https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:110046
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:1100462020-03-04 00:00:002020-03-04 00:00:00Dendritic cell vaccine for the effective immunotherapy of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-03 / Clin Transl Immunology 2020;9(3):e1117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-03 / Clin Transl Immunology 2020;9(3):e11172020-03-03 00:00:002020-03-03 00:00:00Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 03;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 Mar;8(1)2020-03-01 00:00:002020-03-01 00:00:00T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-27 / Cancers (Basel) 2020 Feb;12(3)2020-02-27 00:00:002020-02-27 00:00:00Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-42972020-02-26 00:00:002022-09-29 14:03:50Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-1027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-10272020-02-22 00:00:002020-08-26 14:19:05Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Front Oncol 2020;10:187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-772020-02-21 00:00:002020-02-21 00:00:00[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-13872020-02-20 00:00:002020-02-20 00:00:00Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
